Organogenesis Holdings Inc.

Organogenesis Holdings Inc. (Nasdaq: ORGO), a commercial-stage regenerative medicine company focused on advanced wound care and surgical biologics, went public in 2018 through a SPAC business combination with Avista Healthcare Public Acquisition Corp, sponsored by Avista Capital Holdings. The company filed an 8-K current report with the Securities and Exchange Commission on June 16, 2026, disclosing a material corporate event. ORGO continues to trade on Nasdaq as an established post-merger public company operating across the regenerative medicine and wound care sectors. For full filing details, sponsor history, and SPAC analytics on ORGO and thousands of other vehicles, sign up for SpacDesk.